Lido Advisors LLC Acquires 9,154 Shares of Bio-Techne Corp $TECH

Lido Advisors LLC acquired a new stake in Bio-Techne Corp (NASDAQ:TECH – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 9,154 shares of the biotechnology company’s stock, valued at approximately $663,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Root Financial Partners LLC purchased a new position in Bio-Techne in the 3rd quarter worth about $27,000. Cassaday & Co Wealth Management LLC bought a new stake in Bio-Techne during the 1st quarter valued at about $37,000. Avalon Trust Co purchased a new stake in Bio-Techne in the 2nd quarter valued at about $42,000. Allworth Financial LP purchased a new stake in Bio-Techne in the 2nd quarter valued at about $59,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Bio-Techne in the 2nd quarter valued at about $71,000. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Bio-Techne Price Performance

TECH stock opened at $72.75 on Thursday. The business has a 50-day moving average price of $72.56 and a 200 day moving average price of $63.60. The company has a market capitalization of $11.43 billion, a P/E ratio of 41.98, a PEG ratio of 5.27 and a beta of 1.29. Bio-Techne Corp has a 1-year low of $43.19 and a 1-year high of $72.88.

Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its earnings results on Monday, November 9th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.44. Bio-Techne had a net margin of 13.95% and a return on equity of 13.00%. The company had revenue of $299.71 million for the quarter, compared to analysts’ expectations of $292.60 million. On average, analysts anticipate that Bio-Techne Corp will post 1.75 earnings per share for the current fiscal year.

Bio-Techne Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 23rd. Stockholders of record on Friday, November 13th will be issued a $0.08 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.32 annualized dividend and a dividend yield of 0.4%. This is a decrease from Bio-Techne’s previous quarterly dividend of $0.65. Bio-Techne’s dividend payout ratio (DPR) is presently 29.36%.

Analyst Upgrades and Downgrades

TECH has been the topic of a number of research analyst reports. Zacks Research upgraded shares of Bio-Techne from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 29th. Wells Fargo & Company lowered Bio-Techne from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $62.00 to $73.00 in a report on Thursday, August 13th. Weiss Ratings upgraded Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Benchmark reissued a “hold” rating on shares of Bio-Techne in a research note on Wednesday, August 19th. Finally, Argus downgraded Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bio-Techne currently has a consensus rating of “Hold” and a consensus target price of $68.92.

Read Our Latest Report on TECH

Bio-Techne Company Profile

(Free Report)

Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.

Featured Stories

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH – Free Report).

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.